Merck & Co., Inc. (NYSE: MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Employees of the technology transfer center ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Celonis bullish on India's growing global capability centre landscape, offering process intelligence through digital twins to ...

Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

The scale of the Merck layoffs has not been revealed, but the company indicated that it would target roles in the ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...